- Home
- TCRX vs IOBT Comparison
TCRX vs IOBT Comparison
Compare TCRX & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TCRX | IOBT |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.6M | 26.6M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TCRX | IOBT |
|---|---|---|
| Price | $1.15 | $0.25 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 4 |
| Target Price | ★ $8.00 | $2.25 |
| AVG Volume (30 Days) | 490.6K | ★ 865.4K |
| Earning Date | 06-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 12.28 | ★ 26.77 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,325,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $69.75 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 266.65 | N/A |
| 52 Week Low | $0.88 | $0.21 |
| 52 Week High | $2.57 | $2.79 |
Technical Indicators
Market Signals| Indicator | TCRX | IOBT |
|---|---|---|
| Relative Strength Index (RSI) | 56.64 | 31.43 |
| Support Level | $0.90 | $0.21 |
| Resistance Level | $1.23 | $0.40 |
| Average True Range (ATR) | 0.08 | 0.03 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 62.41 | 0.98 |
Price Performance
Historical ComparisonAbout TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.